Key statistics
On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 5.28, 39.31% above the 52 week low of 3.79 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.56 |
---|---|
High | 5.61 |
Low | 5.25 |
Bid | 5.28 |
Offer | 5.30 |
Previous close | 5.72 |
Average volume | 32.98m |
---|---|
Shares outstanding | 433.58m |
Free float | 369.04m |
P/E (TTM) | -- |
Market cap | 2.48bn USD |
EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
- Recursion to Participate in Upcoming Investor Conferences
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
- Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
- Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
- Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
- Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
- Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
More ▼